Skip to main content

Compare Stocks

Date Range: 

 Helix BioPharmaMereo BioPharma GroupCelsionRecro PharmaCocrystal Pharma
SymbolOTCMKTS:HBPCFNASDAQ:MREONASDAQ:CLSNNASDAQ:REPHNASDAQ:COCP
Price Information
Current Price$0.76$3.21$1.14$2.51$1.16
52 Week RangeN/ABuyHoldBuyBuy
MarketRank™
Overall Score0.51.51.31.11.4
Analysis Score0.03.53.00.03.5
Community Score2.32.42.72.62.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.80.0
Earnings & Valuation Score0.00.60.61.90.6
Analyst Ratings
Consensus RecommendationN/ABuyHoldBuyBuy
Consensus Price TargetN/A$10.00$4.00N/A$4.75
% Upside from Price TargetN/A211.53% upside250.88% upsideN/A309.48% upside
Trade Information
Market Cap$107.80 million$199.31 million$95.21 million$78.50 million$80.05 million
Beta0.041.692.421.251.46
Average Volume1,6642,069,80213,880,340588,41911,645,030
Sales & Book Value
Annual RevenueN/AN/A$500,000.00$99.22 million$6.56 million
Price / SalesN/AN/A197.350.7817.24
CashflowN/AN/AN/A$0.49 per share$0.97 per share
Price / CashN/AN/AN/A5.101.20
Book Value$0.02 per share$2.06 per share$0.63 per share($0.30) per share$0.73 per share
Price / BookN/AN/A1.81-8.371.59
Profitability
Net Income$-6,680,000.00$-44,490,000.00$-16,850,000.00$-18,630,000.00$-48,170,000.00
EPSN/A($2.49)($0.91)$0.20($0.06)
Trailing P/E Ratio0.00N/AN/A12.55N/A
Forward P/E Ratio∞N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-4,315.00%-34.14%-2,938.09%
Return on Equity (ROE)-325.42%N/A-104.32%N/A-25.81%
Return on Assets (ROA)-193.46%N/A-47.65%-18.97%-23.98%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.60%0.25%N/AN/A
Current Ratio2.22%2.99%3.67%3.95%12.59%
Quick Ratio2.22%N/A3.67%3.17%12.59%
Ownership Information
Institutional Ownership PercentageN/A62.14%13.73%56.34%18.71%
Insider Ownership Percentage7.60%N/A20.49%23.10%10.80%
Miscellaneous
Employees10382718513
Shares Outstanding141.13 million67.79 million86.56 million31.03 million97.47 million
Next Earnings Date7/29/2021 (Estimated)6/30/2021 (Estimated)8/13/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Cocrystal Pharma (NASDAQ:COCP) Issues Quarterly Earnings ResultsCocrystal Pharma (NASDAQ:COCP) Issues Quarterly Earnings Results
americanbankingnews.com - May 18 at 10:48 AM
Cocrystal Pharma Inc. [COCP] moved up 4.63: Why It’s ImportantCocrystal Pharma Inc. [COCP] moved up 4.63: Why It’s Important
dbtnews.com - May 17 at 6:37 PM
Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock hinders -1.69%, but it may be a worthy investmentCocrystal Pharma, Inc. (NASDAQ:COCP)’s stock hinders -1.69%, but it may be a worthy investment
stocksregister.com - May 17 at 3:28 PM
Future Outlook And Stock Price Performance For Cocrystal Pharma, Inc. (NASDAQ:COCP)Future Outlook And Stock Price Performance For Cocrystal Pharma, Inc. (NASDAQ:COCP)
marketingsentinel.com - May 17 at 10:28 AM
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business UpdateCocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 17 at 8:36 AM
Cocrystal Pharma Inc. (NASDAQ:COCP) surprises bull, looks strong going forwardCocrystal Pharma Inc. (NASDAQ:COCP) surprises bull, looks strong going forward
marketingsentinel.com - May 11 at 12:30 PM
Analysts think Cocrystal Pharma, Inc. (NASDAQ:COCP) could rise 260% from current levelsAnalysts think Cocrystal Pharma, Inc. (NASDAQ:COCP) could rise 260% from current levels
stocksregister.com - May 10 at 4:27 PM
Cocrystal Pharma Announces Closing of $40 Million Bought DealCocrystal Pharma Announces Closing of $40 Million Bought Deal
finance.yahoo.com - May 7 at 5:01 PM
Cocrystal Pharma, Inc. (NASDAQ:COCP) Major Shareholder Sells $1,696,250.00 in StockCocrystal Pharma, Inc. (NASDAQ:COCP) Major Shareholder Sells $1,696,250.00 in Stock
americanbankingnews.com - May 6 at 8:42 PM
Cocrystal Pharma Inc. [COCP] Stock trading around $2.14 per share: What’s Next?Cocrystal Pharma Inc. [COCP] Stock trading around $2.14 per share: What’s Next?
dbtnews.com - May 5 at 5:27 PM
Rookie Traders Get Crushed By Cocrystal Pharma StockRookie Traders Get Crushed By Cocrystal Pharma Stock
msn.com - May 5 at 12:26 PM
Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% DiscountCocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount
finance.yahoo.com - May 5 at 12:26 PM
Cocrystal stock pulls back sharply after stock offering priced to the public at a deep discountCocrystal stock pulls back sharply after stock offering priced to the public at a deep discount
finance.yahoo.com - May 5 at 12:26 PM
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common StockCocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
finance.yahoo.com - May 4 at 7:43 PM
Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidatesCocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates
finance.yahoo.com - May 4 at 2:51 PM
Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving TodayWhy Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today
markets.businessinsider.com - May 4 at 2:42 PM
Cocrystal Doubles on Report of Progress on Covid DrugsCocrystal Doubles on Report of Progress on Covid Drugs
finance.yahoo.com - May 4 at 2:42 PM
Thinking about buying stock in BioLineRx, Cocrystal Pharma, Vaxart, Precipio, or Arrival?Thinking about buying stock in BioLineRx, Cocrystal Pharma, Vaxart, Precipio, or Arrival?
wfmz.com - May 4 at 10:39 AM
Cocrystal Soars on New Drug CandidatesCocrystal Soars on New Drug Candidates
baystreet.ca - May 4 at 10:39 AM
Cocrystal Pharma (COCP) Stock Rockets On COVID-19 NewsCocrystal Pharma (COCP) Stock Rockets On COVID-19 News
cnafinance.com - May 4 at 9:42 AM
Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral CandidateCocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate
finance.yahoo.com - May 3 at 5:39 PM
BRIEF-Cocrystal Pharma Provides Update On COVID-19 Antiviral Discovery And Development ProgramsBRIEF-Cocrystal Pharma Provides Update On COVID-19 Antiviral Discovery And Development Programs
msn.com - May 3 at 8:58 AM
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development ProgramsCocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
finance.yahoo.com - May 3 at 8:14 AM
Cocrystal Pharma, Inc. (NASDAQ:COCP)’s -6.72% Fall This Week Just Tells Us Something NewCocrystal Pharma, Inc. (NASDAQ:COCP)’s -6.72% Fall This Week Just Tells Us Something New
marketingsentinel.com - May 1 at 8:15 AM
Is It Safe to Invest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Now?Is It Safe to Invest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Now?
stocksregister.com - April 24 at 5:39 PM
DateCompanyBrokerageAction
5/11/2021Mereo BioPharma GroupBTIG ResearchInitiated Coverage
4/5/2021Mereo BioPharma GroupNeedham & Company LLCInitiated Coverage
10/10/2019Mereo BioPharma GroupSVB LeerinkReiterated Rating
7/16/2020CelsionOppenheimerDowngrade
7/13/2020CelsionDawson JamesDowngrade
7/25/2019CelsionBrookline Capital ManagementReiterated Rating
1/4/2021Recro PharmaCraig HallumInitiated Coverage
3/5/2020Recro PharmaStephensLower Price Target
3/25/2019Recro PharmaRoth CapitalReiterated Rating
1/31/2019Recro PharmaJanney Montgomery ScottReiterated Rating
11/8/2018Recro PharmaPiper Jaffray CompaniesSet Price Target
11/18/2020Cocrystal PharmaNoble FinancialReiterated Rating
11/12/2020Cocrystal PharmaHC WainwrightLower Price Target
7/17/2018Cocrystal PharmaEuroPacific CanadaInitiated Coverage
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.